The company has not filed an annual or quarterly report since its Q3 FY2020 10-Q, filed Nov 6, 2020. Its latest SEC filing is a SC 13G/A from Feb 16, 2021.
10-Q for Q3 FY2020, filed Nov 6, 2020
The sections below describe the company as of the FY2019 annual report.
Develops PRINT-engineered drug products for patients, including an inhaled dry-powder treprostinil treatment for pulmonary arterial hypertension and an injectable sustained-release anesthetic for post-operative pain; also works with pharmaceutical companies on drug development.
10-K for FY2019, filed Mar 16, 2020We are a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing our…View ↗
LIQ865 is our proprietary injectable, sustained-release formulation of bupivacaine, a non-opioid pain medication. We have engineered the…View ↗
In addition to building our own internal pipeline, we may collaborate with pharmaceutical companies to assist in the development of their…View ↗
Liquidia earns fees by licensing its PRINT technology and doing research and development for pharmaceutical partners. Partners pay upfront and additional amounts when development or regulatory goals are met; research work is billed quarterly based on time and materials, and royalties are tied to product sales.
10-K for FY2019, filed Mar 16, 2020The Company derives revenues primarily from licensing its proprietary PRINT technology and from performing research and development…View ↗
The transaction price for these contracts includes non-refundable fees and fees for research and development services. Non-refundable…View ↗
The estimate of the research services to be provided through the Technology Transfer requires significant judgment to evaluate assumptions…View ↗
Royalties related to product sales will be recognized as revenue when the sale occurs since payments relate directly to products that will…View ↗
$8.1M
10-K for FY2019, filed Mar 16, 2020
$8.1M ↗
Pharmaceutical companies contract with Liquidia for PRINT licenses and research and development services. Liquidia plans to market LIQ861 in the U.S. itself or with a pharmaceutical partner and to use regional pharmaceutical partners outside the U.S.
10-K for FY2019, filed Mar 16, 2020In addition to building our own internal pipeline, we may collaborate with pharmaceutical companies to assist in the development of their…View ↗
The Company derives revenues primarily from licensing its proprietary PRINT technology and from performing research and development…View ↗
The Company’s research, development and licensing agreements provide for multiple promised goods and services to be satisfied by the…View ↗
We hold worldwide commercialization rights to LIQ861 and LIQ865. We are currently exploring opportunities to commercialize LIQ861 in the…View ↗
No. It lost $47.6M in FY2019.
10-K for FY2019, filed Mar 16, 2020
10-K for FY2019, filed Mar 16, 2020
−$46.8MView ↗
10-K for FY2019, filed Mar 16, 2020
−$47.6MView ↗
10-K for FY2019, filed Mar 16, 2020
−$50.1MView ↗
10-Q for Q3 FY2020, filed Nov 6, 2020
−$15MView ↗
8-K, filed Nov 18, 2020
On November 18, 2020 (the “Closing Date”), Liquidia Technologies, Inc., a Delaware corporation (“Liquidia Technologies”), completed the…View ↗
8-K, filed Aug 20, 2020
On August 20, 2020 (the “Appointment Date”), Steven Bariahtaris was appointed by the Board of Directors (the “Board”) of Liquidia…View ↗
Grew. Revenue grew 11% in 2 years, from $7.3M in FY2017 to $8.1M in FY2019, about 5% a year.
Loading...
